iHealthcareAnalyst, Inc. Announced Dyslipidemia Drugs Market to Reach USD 9.5 Billion by 2020, Decline Due to Patent Expiration and Limited Drugs Innovation
Dyslipidemia Drugs Market – Global Dyslipidemia Drug Classes Analysis and Forecast 2013-2020.
Maryland Heights, MO, July 16, 2016 --(PR.com)-- Dyslipidemia Drugs Market – Global Dyslipidemia Drug Classes Analysis and Forecast 2013-2020, estimates the global dyslipidemia drugs market decline to reach nearly USD 9.5 Billion in 2020, at a CAGR of 10.3% from 2016 to 2020 due to patent expirations and absence of new drugs - iHealthcareAnalyst, Inc.
Visit the Dyslipidemia Drugs Market – Global Dyslipidemia Drug Classes Analysis and Forecast 2013-2020 report at http://www.ihealthcareanalyst.com/report/dyslipidemia-drugs-market/
There are four classes of lipid-lowering drugs in the market: the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (the "statins"), the fibrates (gemfibrozil, clofibrate, and fenofibrate), niacin/nicotinic acid, and the bile acid binding resins (colestipol and cholestyramine). The major effects of the lipid lowering drugs include lowering of serum low density lipoprotein (LDL) cholesterol levels which are believed to predispose to atherosclerosis and its complications, acute myocardial infarction, cerebrovascular ischemic stroke and peripheral vascular disease. The dyslipidemia drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug class (bile acid resins, fibric acid and omega-3 fatty acid derivatives, niacin, statins, and other drugs such as combination drugs and cholesterol absorption inhibitors), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.
The global dyslipidemia drugs market is segmented as:
1. Drug Class
1.1. Bile Acid Resins
1.2. Fibric Acid and Omega-3 Fatty Acid Derivatives
1.3. Niacin
1.4. Statins
1.5. Others (Combination Drugs and Cholesterol Absorption Inhibitors)
2. Geography (Region, Country)
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World
3. Company Profiles
3.1. Abbott Laboratories
3.2. Amgen, Inc.
3.3. AstraZeneca plc.
3.4. Bayer AG
3.5. Bristol-Myers Squibb Company
3.6. Merck & Co., Inc.
3.7. Mylan N.V.
3.8. Novartis AG
3.9. Pfizer, Inc.
3.10. Shionogi & Co., Ltd.
3.11. Takeda Pharmaceutical Company Limited
3.12. Teva Pharmaceutical Industries Ltd.
About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareranalyst.com
Website: http://www.ihealthcareanalyst.com
Visit the Dyslipidemia Drugs Market – Global Dyslipidemia Drug Classes Analysis and Forecast 2013-2020 report at http://www.ihealthcareanalyst.com/report/dyslipidemia-drugs-market/
There are four classes of lipid-lowering drugs in the market: the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (the "statins"), the fibrates (gemfibrozil, clofibrate, and fenofibrate), niacin/nicotinic acid, and the bile acid binding resins (colestipol and cholestyramine). The major effects of the lipid lowering drugs include lowering of serum low density lipoprotein (LDL) cholesterol levels which are believed to predispose to atherosclerosis and its complications, acute myocardial infarction, cerebrovascular ischemic stroke and peripheral vascular disease. The dyslipidemia drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug class (bile acid resins, fibric acid and omega-3 fatty acid derivatives, niacin, statins, and other drugs such as combination drugs and cholesterol absorption inhibitors), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.
The global dyslipidemia drugs market is segmented as:
1. Drug Class
1.1. Bile Acid Resins
1.2. Fibric Acid and Omega-3 Fatty Acid Derivatives
1.3. Niacin
1.4. Statins
1.5. Others (Combination Drugs and Cholesterol Absorption Inhibitors)
2. Geography (Region, Country)
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World
3. Company Profiles
3.1. Abbott Laboratories
3.2. Amgen, Inc.
3.3. AstraZeneca plc.
3.4. Bayer AG
3.5. Bristol-Myers Squibb Company
3.6. Merck & Co., Inc.
3.7. Mylan N.V.
3.8. Novartis AG
3.9. Pfizer, Inc.
3.10. Shionogi & Co., Ltd.
3.11. Takeda Pharmaceutical Company Limited
3.12. Teva Pharmaceutical Industries Ltd.
About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareranalyst.com
Website: http://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 736-9294
http://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 736-9294
http://www.ihealthcareanalyst.com/
Contact
Categories